The Value of Shorter Initial Opioid Prescriptions: A Simulation Evaluation
ConclusionThe analysis found that efforts to change prescriber behavior can be cost effective, and further studies into the implementation of such policies are warranted. (Source: PharmacoEconomics)
Source: PharmacoEconomics - October 21, 2019 Category: Health Management Source Type: research

Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment
ConclusionsModeling choices can have a substantial impact on VOI. Therefore, it is important for groups working to incorporate VOI into research prioritization to adhere to best practices, be clear in their reporting and justification for modeling choices, and to work closely with the relevant decision makers, with particular attention to modeling choices. (Source: PharmacoEconomics)
Source: PharmacoEconomics - October 21, 2019 Category: Health Management Source Type: research

Transparency in Health Economic Modeling: Options, Issues and Potential Solutions
AbstractEconomic models are increasingly being used by health economists to assess the value of health technologies and inform healthcare decision making. However, most published economic models represent a kind of black box, with known inputs and outputs but undisclosed internal calculations and assumptions. This lack of transparency makes the evaluation of the model results challenging, complicates comparisons between models, and limits the reproducibility of the models. Here, we aim to provide an overview of the possible steps that could be undertaken to make economic models more transparent and encourage model develope...
Source: PharmacoEconomics - October 8, 2019 Category: Health Management Source Type: research

Bayesian Hierarchical Models for Meta-Analysis of Quality-of-Life Outcomes: An Application in Multimorbidity
ConclusionBayesian hierarchical models may provide a useful modelling approach to systematically synthesize data from HRQoL studies. (Source: PharmacoEconomics)
Source: PharmacoEconomics - October 4, 2019 Category: Health Management Source Type: research

Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians
AbstractThe incidence of hepatocellular carcinoma (HCC) is increasing worldwide, with significant morbidity and associated costs. Treatment allocation depends on the stage of diagnosis; however, resource utilization can be significant across all stages. We aimed to summarize the available data on the cost effectiveness of surveillance of and treatments for HCC in the context of current treatment guidelines. We performed a focused review of studies investigating the economic burden and cost effectiveness of HCC surveillance treatment modalities published between January 2000 and January 2019. The overall economic burden of ...
Source: PharmacoEconomics - October 1, 2019 Category: Health Management Source Type: research

A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost ‑Effectiveness Analysis
ConclusionsDifferent approaches used in fitting parametric survival distributions yielded predicted probabilities that substantially differed from those using original IPD. Our study highlights the importance of following guidelines for economic evaluations with a systematic approach to parametric survival analysis techniques in order to select best fitting parametric survival distributions. (Source: PharmacoEconomics)
Source: PharmacoEconomics - October 1, 2019 Category: Health Management Source Type: research

Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design
DiscussionThis review provides an overview of how CKD is typically modelled. While common frameworks were identified, model structure varied, and no single model type was used for the modelling of patients with CKD. In addition, many of the current methods did not explicitly consider patient heterogeneity or underlying disease aetiology, except for diabetes. However, the variability of individual patients ’ GFR and albuminuria trajectories perhaps provides rationale for a model structure designed around the prediction of individual patients’ GFR trajectories. Frameworks of future CKD models should be informed a...
Source: PharmacoEconomics - September 30, 2019 Category: Health Management Source Type: research

Could or Should We Use MCDA in the French HTA Process?
(Source: PharmacoEconomics)
Source: PharmacoEconomics - September 30, 2019 Category: Health Management Source Type: research

Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies
ConclusionsConsidering the increasing use of unanchored comparative analyses for novel cancer treatments based on single-arm studies, the proposed method offers a relatively simple means of improving the accuracy of relative benefits of treatments on progression times. (Source: PharmacoEconomics)
Source: PharmacoEconomics - September 26, 2019 Category: Health Management Source Type: research

A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling
AbstractThe use of open-source programming languages, such as R, in health decision sciences is growing and has the potential to facilitate model transparency, reproducibility, and shareability. However, realizing this potential can be challenging. Models are complex and primarily built to answer a research question, with model sharing and transparency relegated to being secondary goals. Consequently, code is often neither well documented nor systematically organized in a comprehensible and shareable approach. Moreover, many decision modelers are not formally trained in computer programming and may lack good coding practic...
Source: PharmacoEconomics - September 24, 2019 Category: Health Management Source Type: research

Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Na ïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
ConclusionOur analysis suggests that VDZ is dominant or cost-effective compared with other branded biologics for the treatment of anti-TNF-na ïve patients with moderate-to-severe UC in Japan. (Source: PharmacoEconomics)
Source: PharmacoEconomics - September 24, 2019 Category: Health Management Source Type: research

Cooking Up a Transparent Model Following a DICE Recipe
AbstractWhen a model is built, it tends to be an iterative process. The ideal model building process starts with constructing a top-level model (that works) and then digging deeper into the sections that need more details. A good model tends to have a long life and be both adapted and updated. A perfectly transparent first model (in whatever platform or programming language it might be) therefore tends to get increasingly convoluted. Yet, it still needs to be submitted and reviewed since it will likely be used as support to facilitate possibly multi-million Euro decisions. So, any modelling method should be able to accept ...
Source: PharmacoEconomics - September 23, 2019 Category: Health Management Source Type: research

The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments
ConclusionRisk-sharing contracts are increasingly used, although the lack of transparency and aggregated registries makes it difficult to learn from these experiences and assess their impact on healthcare systems. (Source: PharmacoEconomics)
Source: PharmacoEconomics - September 18, 2019 Category: Health Management Source Type: research

Can You Repeat That? Exploring the Definition of a Successful Model Replication in Health Economics
AbstractThe International Society for Pharmacoeconomics and Outcomes Research (ISPOR) modelling taskforce suggests decision models should be thoroughly reported and transparent. However, the level of transparency and indeed how transparency should be assessed are yet to be defined. One way may be to attempt to replicate the model and its outputs. The ability to replicate a decision model could demonstrate adequate reporting transparency. This review aims to explore published definitions of replication success across all scientific disciplines and to consider how such a definition should be tailored for use in health econom...
Source: PharmacoEconomics - September 18, 2019 Category: Health Management Source Type: research

Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study
AbstractBackgroundA limited evidence base and lack of clear clinical guidelines challenge healthcare systems ’ adoption of precision medicine. The effect of these conditions on demand is not understood.ObjectiveThis research estimated the public ’s preferences and demand for precision medicine outcomes.MethodsA discrete-choice experiment survey was conducted with an online sample of the US public who had recent healthcare experience. Statistical analysis was undertaken using an error components mixed logit model. The responsiveness of demand in the context of a changing evidence base was estimated through the p...
Source: PharmacoEconomics - September 6, 2019 Category: Health Management Source Type: research

Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States
AbstractTransparency in decision modeling remains a topic of rigorous debate among healthcare stakeholders, given tensions between the potential benefits of external access during model development and the need to protect intellectual property and reward research investments. Strategies to increase decision model transparency by allowing direct external access to a model ’s structure, source code, and data can take on many forms but are bounded between the status quo and free publicly available open-source models. Importantly, some level of transparency already exists in terms of methods and other technical specifica...
Source: PharmacoEconomics - September 5, 2019 Category: Health Management Source Type: research

Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
CORE diabetes model was used throughout the article for consistency. (Source: PharmacoEconomics)
Source: PharmacoEconomics - September 4, 2019 Category: Health Management Source Type: research

A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
ConclusionsBaricitinib, compared to other DMARDs, was a less expensive option ( − $US0.01 incremental cost per member per month in second- and third-line therapy over a 2-year time horizon) with comparable efficacy in patients with inadequate response to TNFi. Adding baricitinib to formulary would likely be cost saving for US payers and expands treatment options for these p atients. (Source: PharmacoEconomics)
Source: PharmacoEconomics - August 27, 2019 Category: Health Management Source Type: research

Comment on: ‘The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study’
(Source: PharmacoEconomics)
Source: PharmacoEconomics - August 26, 2019 Category: Health Management Source Type: research

Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review
ConclusionsFor transplant-eligible MM patients, transplant is a cost-effective first-line treatment. More cost-effectiveness analyses comparing novel agents in the first-line treatment regimen are warranted to determine which agent or regimen is the most cost effective. In the second-line setting, it is unclear which novel agent-based regimen is most cost effective, but bortezomib-based regimens, lenalidomide plus dexamethasone, and pomalidomide plus dexamethasone were each cost effective compared with dexamethasone alone. (Source: PharmacoEconomics)
Source: PharmacoEconomics - August 7, 2019 Category: Health Management Source Type: research

Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project
AbstractThe Innovation and Value Initiative started the Open-Source Value Project with the aim to improve the credibility and relevance of model-based value assessment in the context of the US healthcare environment. As a core activity of the Open-Source Value Project, the Innovation and Value Initiative develops and provides access to flexible open-source economic models that are developed iteratively based on public feedback and input. In this article, we describe our experience to date with the development of two currently released, Open-Source Value Project models, one in rheumatoid arthritis and one in epidermal growt...
Source: PharmacoEconomics - August 7, 2019 Category: Health Management Source Type: research

Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn ’s Disease
ConclusionsThe model supports the use of Inflecta® for Crohn ’s disease in the UK, and provides a framework for the quantitative evaluation of biosimilars in the context of a health technology assessment. Value-based pricing using this methodology could protect health systems from the potential risks of biosimilars where they are untested in the approved po pulations. (Source: PharmacoEconomics)
Source: PharmacoEconomics - August 2, 2019 Category: Health Management Source Type: research

Performance of the UKPDS Outcomes Model  2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort
This study aims to analyze the calibration and discrimination of the updated UKPDS risk equations as implemented in the UKPDS Outcomes Model  2 (UKPDS-OM2) for predicting cardiovascular (CV) events and death in patients with type 2 diabetes mellitus (T2DM) from population-based German samples.MethodsAnalyses are based on data of 456 individuals diagnosed with T2DM who participated in two population-based studies in southern Germany (KORA (Cooperative Health Research in the Region of Augsburg)-A: 1997/1998,n = 178; KORA-S4: 1999–2001,n = 278). We compared the participants’ 1...
Source: PharmacoEconomics - July 27, 2019 Category: Health Management Source Type: research

The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood
AbstractTransparency in health economic decision modelling is important for engendering confidence in the models and in the reliability of model-based cost-effectiveness analyses. The Mount Hood Diabetes Challenge Network has taken a lead in promoting transparency through validation with biennial conferences in which diabetes modelling groups meet to compare simulated outcomes of pre-specified scenarios often based on the results of pivotal clinical trials. Model registration is a potential method for promoting transparency, while also reducing the duplication of effort. An important network initiative is the ongoing const...
Source: PharmacoEconomics - July 26, 2019 Category: Health Management Source Type: research

Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II —An Updated Analysis of SEER-Medicare Data
ConclusionThe rising economic burden of RCC was most pronounced among patients with distant-stage RCC, and driven primarily by new cancer drugs. (Source: PharmacoEconomics)
Source: PharmacoEconomics - July 8, 2019 Category: Health Management Source Type: research

Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013
AbstractBackground and ObjectiveIt is unclear whether private insurance benefit designs align with the most widely used ex-US definition of value, the incremental cost-effectiveness ratio (ICER). A large Pacific Northwest private insurance plan explicitly implemented a tiered formulary based on cost-effectiveness estimates of individual drugs in 2010, resulting in cost savings to the plan without negatively affecting patient health service utilization. Given the pressures of rising costs, we investigate whether employer-based private health insurance plans have adopted value-based cost-sharing approaches that are in line w...
Source: PharmacoEconomics - July 4, 2019 Category: Health Management Source Type: research

Transparency in Decision Modelling: What, Why, Who and How?
AbstractTransparency in decision modelling is an evolving concept. Recently, discussion has moved from reporting standards to open-source implementation of decision analytic models. However, in the debate about the supposed advantages and disadvantages of greater transparency, there is a lack of definition. The purpose of this article is not to present a case for or against transparency, but rather to provide a more nuanced understanding of what transparency means in the context of decision modelling and how it could be addressed. To this end, we review and summarise the discourse to date, drawing on our collective experie...
Source: PharmacoEconomics - June 26, 2019 Category: Health Management Source Type: research

Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand
ConclusionsDespite the proven effectiveness of PCSK9i and ezetimibe, the costs of these agents need to reduce to a much greater extent than in HICs to be cost-effective in Thailand. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 26, 2019 Category: Health Management Source Type: research

Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review
AbstractBorn out of a necessity for fiscal sustainability, simulation modeling is playing an increasingly prominent role in setting priorities for combination implementation strategies for HIV treatment and prevention globally. The design of a model and the data inputted into it are central factors in ensuring credible inferences. We executed a narrative review of a set of dynamic HIV transmission models to comprehensively synthesize and compare the structural design and the quality of evidence used to support each model. We included 19 models representing both generalized and concentrated epidemics, classified as compartm...
Source: PharmacoEconomics - June 21, 2019 Category: Health Management Source Type: research

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
ConclusionsBlinatumomab is estimated to be cost effective versus inotuzumab in R/R B-cell precursor ALL adults who have received one or no prior salvage therapy from a US payer perspective. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 20, 2019 Category: Health Management Source Type: research

Correction to: Publication of Decision Model Source Code: Attitudes of Health Economics Authors
The article Artificial recharge of a shallow hard rock aquiferas a climate change mitigation method. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 19, 2019 Category: Health Management Source Type: research

Decision Models for Assessing the Cost Effectiveness of Treatments for Pediatric Drug-Resistant Epilepsy: A Systematic Review of Economic Evaluations
ConclusionWhether cannabis-based treatments for pediatric drug-resistant epilepsy represent good value for money has yet to be investigated. Economic evaluations of such treatments are needed and should address issues of particular importance in pediatric epilepsy, including weight gain over time, switching or discontinuation of treatments, effectiveness of interventions and comparators, and long-term effectiveness beyond the duration of available clinical studies.PROSPERO RegistrationCRD42018099591. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 14, 2019 Category: Health Management Source Type: research

Cost Effectiveness of Advanced Pharmacy Services Provided in the Community and Primary Care Settings: A Systematic Review
ConclusionsAdvanced pharmacy services appear to be cost effective when delivered in community and primary care settings, but not in domiciliary settings. Expansion in the provision of these services in community and primary care can be recommended for wider implementation. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 10, 2019 Category: Health Management Source Type: research

Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
(Source: PharmacoEconomics)
Source: PharmacoEconomics - June 7, 2019 Category: Health Management Source Type: research

Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe
ConclusionsThe new value set supports consistency with past decisions in cost-utility studies, while offering a better assessment of even moderate improvements in health. It could represent an option for Central and Eastern Europe countries lacking their own value sets. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 3, 2019 Category: Health Management Source Type: research

Mapping the PedsQL ™ onto the CHU9D: An Assessment of External Validity in a Large Community-Based Sample
ConclusionsThe published mapping algorithms have acceptable predictive accuracy as measured by MAE and MSE. The findings of this study indicate that the choice of the most appropriate mapping algorithm to apply may vary according to the population under consideration. (Source: PharmacoEconomics)
Source: PharmacoEconomics - June 3, 2019 Category: Health Management Source Type: research

Severity-Adjusted Probability of Being Cost Effective
ConclusionsHigher willingness-to-pay thresholds for severe diseases are implemented in countries to reflect societal concerns for an equitable distribution of resources. However, the estimates of severity are uncertain, patient populations are heterogeneous, and this can be accounted for with the severity-adjusted probability of being cost effective proposed in this study. The application to the Netherlands suggests that not adopting the new method could result in incorrect decisions in the reimbursement of new health technologies. (Source: PharmacoEconomics)
Source: PharmacoEconomics - May 27, 2019 Category: Health Management Source Type: research

Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
ConclusionsStandard parametric models fitted to the initial ATLANTIC DCO generally underestimated longer-term OS, compared with the later DCO. Cure, parametric mixture and response-based landmark models predicted that larger proportions of patients with metastatic non-small cell lung cancer receiving IO treatments may experience long-term survival, which was more in keeping with the observed data. Further research using more mature OS data for IO treatments is needed. (Source: PharmacoEconomics)
Source: PharmacoEconomics - May 18, 2019 Category: Health Management Source Type: research

Correction to: Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO)
The original article can be found online. (Source: PharmacoEconomics)
Source: PharmacoEconomics - May 16, 2019 Category: Health Management Source Type: research

Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
Correction to Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL. (Source: PharmacoEconomics)
Source: PharmacoEconomics - May 14, 2019 Category: Health Management Source Type: research

Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review
ConclusionsUnderstanding the cost effectiveness of precision medicine is necessary, but not sufficient, evidence for its successful implementation. There are currently few examples of evaluations that have quantified the impact of capacity constraints, which suggests an area of focus for future research. (Source: PharmacoEconomics)
Source: PharmacoEconomics - May 13, 2019 Category: Health Management Source Type: research

Is Reclassification of the Oral Contraceptive Pill from Prescription to Pharmacist-Only Cost Effective? Application of an Economic Evaluation Approach to Regulatory Decisions
ConclusionReclassifying OCPs is likely to be considered cost effective by Australian decision makers. (Source: PharmacoEconomics)
Source: PharmacoEconomics - May 9, 2019 Category: Health Management Source Type: research

Publication of Decision Model Source Code: Attitudes of Health Economics Authors
(Source: PharmacoEconomics)
Source: PharmacoEconomics - May 8, 2019 Category: Health Management Source Type: research

Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
(Source: PharmacoEconomics)
Source: PharmacoEconomics - May 2, 2019 Category: Health Management Source Type: research

Response to ‘Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”’
(Source: PharmacoEconomics)
Source: PharmacoEconomics - May 2, 2019 Category: Health Management Source Type: research

Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions
ConclusionMethodological approaches and assumptions in modeling VE and the indirect effects of childhood vaccination have a major impact on outcomes of decision-analytic models and cost-effectiveness estimates. Considering recently observed trends in the epidemiology of pneumococcal serotypes, there is currently inconclusive evidence regarding the cost effectiveness of pneumococcal vaccination of the elderly due to lack of studies that model key serotypes such as serotype 3 separately from other groups of serotypes. (Source: PharmacoEconomics)
Source: PharmacoEconomics - April 26, 2019 Category: Health Management Source Type: research

Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review
ConclusionsInterpretation of cost-effectiveness data should be treated with caution in this case; details of the therapeutic regimen, such as dosage and frequency, and clinical efficacy of the treatments should be considered in relation to policy-making decisions. Given the scarcity of resources, the ever-increasing significance of health technology assessment, and the substantial differences in the methodologies of the studies presented in this review, there is a pressing need for more advanced and standardised approaches to assessing the effectiveness and cost effectiveness of the emerging anti-VEGF pharmacotherapies for...
Source: PharmacoEconomics - April 22, 2019 Category: Health Management Source Type: research

Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
AbstractThe National Institute for Health and Care Excellence (NICE) invited the company that manufactures ceritinib (Zykadia®, Novartis) to submit evidence on the clinical and cost effectiveness of the drug, as a first-line treatment for adults with anaplastic lymphoma kinase (ALK)-positive (+) advanced non-small-cell lung cancer (NSCLC), as part of the Institute ’s single technology appraisal (STA) process. The CRD (Centre for Reviews and Dissemination) and CHE (Centre for Health Economics) Technology Assessment Group at the University of York was commissioned to act as the Evidence Review Group (ERG). This pap...
Source: PharmacoEconomics - April 16, 2019 Category: Health Management Source Type: research

Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25  Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
This article presents a summary of the Evidence Review Group’s (ERG’s) independent review of the evidence submission, the committee’s deliberations, and the subsequent development of NICE guidance for the use of tisagenlecleucel on the National Health Service (NHS) in England. Tisagenlecleucel is a chimeric antigen receptor-modified T-cell (CAR-T) product, the first of this emerging therapeutic class to be considered by NICE in this indication. The company’s evidence submission was based upon three single-arm, phase II studies: ELIANA, ENSIGN, and B2101J. These trials d emonstrated a beneficial effe...
Source: PharmacoEconomics - April 13, 2019 Category: Health Management Source Type: research

A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator ’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck
AbstractObjectivesIn the CheckMate 141 trial (NCT02105636), nivolumab demonstrated survival, health-related quality of life, and healthcare resource utilization benefits vs single-agent therapy of investigator ’s choice (IC) (methotrexate, docetaxel or cetuximab) in patients with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). We assessed between-treatment differences in quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) .MethodsSurvival data from CheckMate 141 (nivolumab,n = 240; IC,n = 121) was partitione...
Source: PharmacoEconomics - April 10, 2019 Category: Health Management Source Type: research